or Try an Advanced Search...

    Technical Analysis for CRVO - CervoMed Inc.

    Grade Last Price % Change Price Change
    F 9.60 0.21% 0.02
    CRVO closed up 0.21 percent on Friday, November 22, 2024, on 2.29 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CRVO trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    Doji - Bullish? Reversal 0.00%
    Multiple of Ten Bearish Other 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 0.21%
    NR7 Range Contraction 0.21%
    Narrow Range Bar Range Contraction 0.21%
    Lower Bollinger Band Walk Weakness 0.21%
    Older End-of-Day Signals for CRVO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 1 day ago
    Rose Above Previous Day's High 1 day ago
    2x Volume Pace 1 day ago
    1.5x Volume Pace 1 day ago
    Outside Day 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CRVO Chart by TradingView
    Basic chart:

    Profile

    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Oxygen Dermatology Macular Degeneration Blastoma Glioblastoma Radiation Therapy Signal Transduction Cancer Cell Acne Brain Tumor mTOR Glioblastoma Multiforme Acne Vulgaris Oncology Applications

    Is CRVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 CervoMed Announces Key Senior Leadership Appointments
    Nov 12 CervoMed GAAP EPS of -$0.55 misses by $0.17, revenue of $1.94M misses by $0.3M
    Nov 12 CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
    Nov 8 CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
    Nov 4 CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
    Oct 29 CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
    Oct 15 CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
    Oct 4 CervoMed Ends $20 Million Stock Sales Agreement with BTIG
    Oct 3 CervoMed files for $250M mixed securities shelf
    Oct 2 CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
    See more CRVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.3789
    52 Week Low 5.85
    Average Volume 83,261
    200-Day Moving Average 17.17
    50-Day Moving Average 13.27
    20-Day Moving Average 11.80
    10-Day Moving Average 10.62
    Average True Range 1.04
    RSI (14) 27.54
    ADX 19.7
    +DI 13.60
    -DI 23.78
    Chandelier Exit (Long, 3 ATRs) 11.50
    Chandelier Exit (Short, 3 ATRs) 12.42
    Upper Bollinger Bands 14.57
    Lower Bollinger Band 9.02
    Percent B (%b) 0.1
    BandWidth 47.10
    MACD Line -1.05
    MACD Signal Line -0.84
    MACD Histogram -0.2088
    Fundamentals Value
    Market Cap 54.48 Million
    Num Shares 5.67 Million
    EPS -5.59
    Price-to-Earnings (P/E) Ratio -1.72
    Price-to-Sales 11.27
    Price-to-Book 5.48
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.10
    Resistance 3 (R3) 11.17 10.73 10.85
    Resistance 2 (R2) 10.73 10.35 10.70 10.77
    Resistance 1 (R1) 10.17 10.12 10.45 10.10 10.68
    Pivot Point 9.73 9.73 9.88 9.70 9.73
    Support 1 (S1) 9.17 9.35 9.45 9.10 8.52
    Support 2 (S2) 8.73 9.12 8.70 8.43
    Support 3 (S3) 8.17 8.73 8.35
    Support 4 (S4) 8.10